ReviewCell & bioscience2025
From pathogenesis to therapeutic targeting: new insight into TAM receptors in rheumatoid arthritis.
Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactylation-Driven PROS1-TYRO3-CARF Signaling Promotes Therapy-Induced Senescence Escape and Radioresistance in Meningioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Receptor-Ligand Biomarker Profile in Ankylosing Spondylitis: Associations BetweenLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Rheumatoid arthritis (RA), a systemic autoimmune disorder driven by chronic joint inflammation and progressive tissue damage, is orchestrated by a complex interplay of immune cells and signaling pathways. Among these, the TAM receptor family, comprising Tyro3, Axl, and MerTK, has emerged as a critical regulator of immune homeostasis and inflammatory resolution. Activation of TAM receptors by their cognate ligands helps restore tissue integrity through key mechanisms including the suppression of innate immune cell activation, enhancement of apoptotic cells (ACs) clearance, and promotion of tissue repair. Given these multifaceted roles, the TAM signaling pathway presents a compelling therapeutic target for RA. This review systematically delineates the biological rationale for targeting TAM receptors in RA, explores their potential as diagnostic biomarkers, and evaluates the current landscape of TAM-directed therapeutics. Ultimately, targeting the TAM axis offers a promising avenue to refine clinical management strategies for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.